Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter?

Cancer Treatment Reviews

Volumn 60, Issue , 2017, Pages 60-68

  Ferrara, Roberto ^a   Mezquita, Laura ^a   Auclin, Edouard ^a   Chaput, Nathalie ^a,b   Besse, Benjamin ^a,b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Age; Anti PD1 PD L1 mAb; Elderly; Immune checkpoint inhibitors; Immunosenescence; Non small cell lung cancer

Indexed keywords

ALPHA INTERFERON; ATEZOLIZUMAB; DOCETAXEL; DURVALUMAB; GAMMA INTERFERON; NIVOLUMAB; PEMBROLIZUMAB; ANTINEOPLASTIC AGENT;

ANGIOGENESIS; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ASTHENIA; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RISK; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COHORT ANALYSIS; DECREASED APPETITE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; HUMAN; HYPOTHYROIDISM; IMMUNOSENESCENCE; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE SUBPOPULATION; NAUSEA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; POPULATION RESEARCH; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RETROSPECTIVE STUDY; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; UPREGULATION; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE CHECKPOINT; CELLULAR IMMUNITY; IMMUNOLOGY; IMMUNOTHERAPY; LUNG NEOPLASMS; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE CHECKPOINTS; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY;

EID: 85028961588     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2017.08.003     Document Type: Review

References (67)

1. Owonikoko, T.K., Ragin, C.C., Belani, C.P., Oton, A.B., Gooding, W.E., Taioli, E., et al. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol Off J Am Soc Clin Oncol 25 (2007), 5570–5577, 10.1200/JCO.2007.12.5435.
2. Gridelli, C., Aapro, M., Ardizzoni, A., Balducci, L., De Marinis, F., Kelly, K., et al. Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel. J Clin Oncol Off J Am Soc Clin Oncol 23 (2005), 3125–3137, 10.1200/JCO.2005.00.224.
3. Fulop, T., Kotb, R., Fortin, C.F., Pawelec, G., de Angelis, F., Larbi, A., Potential role of immunosenescence in cancer development. Ann N Y Acad Sci 1197 (2010), 158–165, 10.1111/j.1749-6632.2009.05370.x.
4. Brahmer, J., Reckamp, K.L., Baas, P., Crinò, L., Eberhardt, W.E.E., Poddubskaya, E., et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373 (2015), 123–135, 10.1056/NEJMoa1504627.
5. Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D.R., Steins, M., Ready, N.E., et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373 (2015), 1627–1639, 10.1056/NEJMoa1507643.
6. Herbst, R.S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J.L., Han, J.-Y., et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet Lond Engl 387 (2016), 1540–1550, 10.1016/S0140-6736(15)01281-7.
7. Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet Lond Engl 389 (2017), 255–265, 10.1016/S0140-6736(16)32517-X.
8. Reck, M., Rodríguez-Abreu, D., Robinson, A.G., Hui, R., Csőszi, T., Fülöp, A., et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375 (2016), 1823–1833, 10.1056/NEJMoa1606774.
9. Gettinger, S.N., Horn, L., Gandhi, L., Spigel, D.R., Antonia, S.J., Rizvi, N.A., et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol 33 (2015), 2004–2012, 10.1200/JCO.2014.58.3708.
10. Hutchins, L.F., Unger, J.M., Crowley, J.J., Coltman, C.A., Albain, K.S., Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341 (1999), 2061–2067, 10.1056/NEJM199912303412706.
11. Nishijima, T.F., Muss, H.B., Shachar, S.S., Moschos, S.J., Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: a systematic review and meta-analysis. Cancer Treat Rev 45 (2016), 30–37, 10.1016/j.ctrv.2016.02.006.
12. Landre T, Taleb C, Nicolas P, Des Guetz G. Is there a clinical benefit of anti-PD-1 in patients older than 75 years with previously treated solid tumour? J Clin Oncol 2017;34(suppl. 15), n.d. < http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.3070> (accessed June 1, 2017).
13. Motzer, R.J., Escudier, B., McDermott, D.F., George, S., Hammers, H.J., Srinivas, S., et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373 (2015), 1803–1813, 10.1056/NEJMoa1510665.
14. Franceschi, C., Valensin, S., Fagnoni, F., Barbi, C., Bonafè, M., Biomarkers of immunosenescence within an evolutionary perspective: the challenge of heterogeneity and the role of antigenic load. Exp Gerontol 34 (1999), 911–921.
15. Weng, N.-P., Akbar, A.N., Goronzy, J., CD28(-) T cells: their role in the age-associated decline of immune function. Trends Immunol 30 (2009), 306–312, 10.1016/j.it.2009.03.013.
16. Lanna, A., Henson, S.M., Escors, D., Akbar, A.N., The kinase p38 activated by the metabolic regulator AMPK and scaffold TAB1 drives the senescence of human T cells. Nat Immunol 15 (2014), 965–972, 10.1038/ni.2981.
17. + T cells. J Clin Invest 124 (2014), 4004–4016, 10.1172/JCI75051.
18. Akbar, A.N., Henson, S.M., Lanna, A., Senescence of T lymphocytes: implications for enhancing human immunity. Trends Immunol 37 (2016), 866–876, 10.1016/j.it.2016.09.002.
19. van de Berg, P.J.E.J., Griffiths, S.J., Yong, S.-L., Macaulay, R., Bemelman, F.J., Jackson, S., et al. Cytomegalovirus infection reduces telomere length of the circulating T cell pool. J Immunol Baltim Md 2010:184 (1950), 3417–3423, 10.4049/jimmunol.0903442.
20. Mirza, N., Duque, M.A., Dominguez, A.L., Schrum, A.G., Dong, H., Lustgarten, J., B7–H1 expression on old CD8+ T cells negatively regulates the activation of immune responses in aged animals. J Immunol Baltim Md 2010:184 (1950), 5466–5474, 10.4049/jimmunol.0903561.
21. Lim, S.J., Kim, J.M., Lee, W.S., Kwon, W.S., Kim, T.S., Park, K.H., et al. Abstract 4055: immune checkpoint protein expression is up-regulated in tumor-bearing elderly mice. Cancer Res, 75, 2015, 10.1158/1538-7445.AM2015-4055 4055–4055.
22. Franceschi, C., Bonafè, M., Valensin, S., Olivieri, F., De Luca, M., Ottaviani, E., et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci 908 (2000), 244–254.
23. Adibzadeh, M., Mariani, E., Bartoloni, C., Beckman, I., Ligthart, G., Remarque, E., et al. Lifespans of T lymphocytes. Mech Ageing Dev 91 (1996), 145–154.
24. Bandrés, E., Merino, J., Vázquez, B., Inogés, S., Moreno, C., Subirá, M.L., et al. The increase of IFN-gamma production through aging correlates with the expanded CD8(+high)CD28(-)CD57(+) subpopulation. Clin Immunol Orlando Fla 96 (2000), 230–235, 10.1006/clim.2000.4894.
25. Effros, R.B., Boucher, N., Porter, V., Zhu, X., Spaulding, C., Walford, R.L., et al. Decline in CD28+ T cells in centenarians and in long-term T cell cultures: a possible cause for both in vivo and in vitro immunosenescence. Exp Gerontol 29 (1994), 601–609.
26. Posnett, D.N., Edinger, J.W., Manavalan, J.S., Irwin, C., Marodon, G., Differentiation of human CD8 T cells: implications for in vivo persistence of CD8+ CD28- cytotoxic effector clones. Int Immunol 11 (1999), 229–241.
27. Plunkett, F.J., Franzese, O., Finney, H.M., Fletcher, J.M., Belaramani, L.L., Salmon, M., et al. The loss of telomerase activity in highly differentiated CD8+CD28-CD27- T cells is associated with decreased Akt (Ser473) phosphorylation. J Immunol Baltim Md 2007:178 (1950), 7710–7719.
28. Voehringer, D., Koschella, M., Pircher, H., Lack of proliferative capacity of human effector and memory T cells expressing killer cell lectinlike receptor G1 (KLRG1). Blood 100 (2002), 3698–3702, 10.1182/blood-2002-02-0657.
29. Onyema, O.O., Decoster, L., Njemini, R., Forti, L.N., Bautmans, I., De Waele, M., et al. Shifts in subsets of CD8+ T-cells as evidence of immunosenescence in patients with cancers affecting the lungs: an observational case-control study. BMC Cancer, 15, 2015, 1016, 10.1186/s12885-015-2013-3.
30. Saavedra, D., García, B., Lorenzo-Luaces, P., González, A., Popa, X., Fuentes, K.P., et al. Biomarkers related to immunosenescence: relationships with therapy and survival in lung cancer patients. Cancer Immunol Immunother CII 65 (2016), 37–45, 10.1007/s00262-015-1773-6.
31. Colonna-Romano, G., Bulati, M., Aquino, A., Scialabba, G., Candore, G., Lio, D., et al. B cells in the aged: CD27, CD5, and CD40 expression. Mech Ageing Dev 124 (2003), 389–393.
32. Carrard, G., Bulteau, A.-L., Petropoulos, I., Friguet, B., Impairment of proteasome structure and function in aging. Int J Biochem Cell Biol 34 (2002), 1461–1474.
33. Lio, D., D'Anna, C., Gervasi, F., Scola, L., Potestio, M., Di Lorenzo, G., et al. Interleukin-12 release by mitogen-stimulated mononuclear cells in the elderly. Mech Ageing Dev 102 (1998), 211–219.
34. Plowden, J., Renshaw-Hoelscher, M., Engleman, C., Katz, J., Sambhara, S., Innate immunity in aging: impact on macrophage function. Aging Cell 3 (2004), 161–167, 10.1111/j.1474-9728.2004.00102.x.
35. Kiertscher, S.M., Luo, J., Dubinett, S.M., Roth, M.D., Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J Immunol Baltim Md 2000:164 (1950), 1269–1276.
36. Khare, V., Sodhi, A., Singh, S.M., Effect of aging on the tumoricidal functions of murine peritoneal macrophages. Nat Immun 15 (1996), 285–294.
37. Butcher, S.K., Chahal, H., Nayak, L., Sinclair, A., Henriquez, N.V., Sapey, E., et al. Senescence in innate immune responses: reduced neutrophil phagocytic capacity and CD16 expression in elderly humans. J Leukoc Biol 70 (2001), 881–886.
38. Borrego, F., Alonso, M.C., Galiani, M.D., Carracedo, J., Ramirez, R., Ostos, B., et al. NK phenotypic markers and IL2 response in NK cells from elderly people. Exp Gerontol 34 (1999), 253–265.
39. d'Adda di Fagagna, F., Living on a break: cellular senescence as a DNA-damage response. Nat Rev Cancer 8 (2008), 512–522, 10.1038/nrc2440.
40. + T cells by both hTERT downregulation and induction of p38 MAPK signaling. J Immunol Baltim Md 2013:191 (1950), 3744–3752, 10.4049/jimmunol.1301409.
41. Farazi, M., Nguyen, J., Goldufsky, J., Linnane, S., Lukaesko, L., Weinberg, A.D., et al. Caloric restriction maintains OX40 agonist-mediated tumor immunity and CD4 T cell priming during aging. Cancer Immunol Immunother CII 63 (2014), 615–626, 10.1007/s00262-014-1542-y.
42. Fontana, L., Partridge, L., Promoting health and longevity through diet: from model organisms to humans. Cell 161 (2015), 106–118, 10.1016/j.cell.2015.02.020.
43. Biagi, E., Candela, M., Turroni, S., Garagnani, P., Franceschi, C., Brigidi, P., Ageing and gut microbes: perspectives for health maintenance and longevity. Pharmacol Res 69 (2013), 11–20, 10.1016/j.phrs.2012.10.005.
44. Tien, M.-T., Girardin, S.E., Regnault, B., Le Bourhis, L., Dillies, M.-A., Coppée, J.-Y., et al. Anti-inflammatory effect of Lactobacillus casei on Shigella-infected human intestinal epithelial cells. J Immunol Baltim Md 2006:176 (1950), 1228–1237.
45. Cho, S.-Y., Kim, J., Lee, J.H., Sim, J.H., Cho, D.-H., Bae, I.-H., et al. Modulation of gut microbiota and delayed immunosenescence as a result of syringaresinol consumption in middle-aged mice. Sci Rep, 6, 2016, 39026, 10.1038/srep39026.
46. Vétizou, M., Pitt, J.M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350 (2015), 1079–1084, 10.1126/science.aad1329.
47. Sivan, A., Corrales, L., Hubert, N., Williams, J.B., Aquino-Michaels, K., Earley, Z.M., et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350 (2015), 1084–1089, 10.1126/science.aac4255.
48. Chaput, N., Lepage, P., Coutzac, C., Soularue, E., Le Roux, K., Monot, C., et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol Off J Eur Soc Med Oncol, 2017, 10.1093/annonc/mdx108.
49. Rizvi, N.A., Mazières, J., Planchard, D., Stinchcombe, T.E., Dy, G.K., Antonia, S.J., et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 16 (2015), 257–265, 10.1016/S1470-2045(15)70054-9.
50. Socinski M, Creelan B, Horn L, Reck M, Paz-Ares L, Steins M, et al. NSCLC, metastaticCheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC. Ann Oncol 2016;27. http://dx.doi.org/10.1093/annonc/mdw435.39.
51. Gettinger, S.N., Horn, L., Ramalingam, S.S., Spigel, D.R., Paz-Ares, L., Paik, P., et al. 3094 Nivolumab (NIVO) safety profile: Summary of findings from trials in patients (pts) with advanced squamous (SQ) non-small cell lung cancer (NSCLC). Eur J Cancer, 51, 2015, S631, 10.1016/S0959-8049(16)31735-X.
52. Spigel D, Schwartzberg L, Waterhouse D, Chandler J, Hussein M, Jotte R, et al. P3.02c-026 Is nivolumab safe and effective in elderly and PS2 patients with non-small cell lung cancer (NSCLC)? Results of CheckMate 153. J Thoracic Oncol, n.d. < http://www.jto.org/article/S1556-0864(16)33062-3/fulltext> [accessed June 1, 2017].
53. Bagley, S., Kothari, S., Aggarwal, C., Bauml, J., Alley, E., Evans, T., et al. P3.02c-028 outcomes of nivolumab in elderly patients (pts) with non-small cell lung cancer (NSCLC). J Thorac Oncol, 12, 2017, S1289, 10.1016/j.jtho.2016.11.1823.
54. Grossi F, Crinò L, Catino A, Canova S, Delmonte A, Ardizzoni A et al. P3.02c-096 use of nivolumab in elderly patients with advanced squamous NSCLC: results from the italian expanded access programme (EAP). J Thorac Oncol, n.d. < http://www.jto.org/article/S1556-0864(16)33133-1/abstract> [accessed June 1, 2017].
55. Herbst R, Garon E, Kim DW, Cho BC, Gadgeel S, Léna H et al. OA03.07 KEYNOTE-010: durable clinical benefit in patients with previously treated, PD-L1-Expressing NSCLC who completed pembrolizumab. J Thorac Oncol, n.d. < http://www.jto.org/article/S1556-0864(16)31484-8/fulltext> [accessed June 1, 2017].
56. Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet Lond Engl 387 (2016), 1837–1846, 10.1016/S0140-6736(16)00587-0.
57. Gadgeel S, Ciardiello F, Rittmeyer A, Barlesi F, Cortinovis D, Barrios C et al. PL04a.02: OAK, a randomized Ph III study of atezolizumab vs docetaxel in patients with advanced NSCLC: results from subgroup analyses. J Thorac Oncol, n.d. < http://www.jto.org/article/S1556-0864(16)31252-7/abstract> [accessed June 1, 2017].
58. Boyerinas, B., Jochems, C., Fantini, M., Heery, C.R., Gulley, J.L., Tsang, K.Y., et al. Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol Res 3 (2015), 1148–1157, 10.1158/2326-6066.CIR-15-0059.
59. Jerusalem G, Chen F, Spigel D, Iannotti N, Mcclay E, Redfern C et al. OA03.03 JAVELIN solid tumor: safety and clinical activity of avelumab (Anti-PD-L1) as first-line treatment in patients with advanced NSCLC. J Thorac Oncol, n.d. < http://www.jto.org/article/S1556-0864(16)31481-2/abstract> [accessed June 1, 2017].
60. Garassino, M., Vansteenkiste, J., Kim, J.-H., Léna, H., Mazières, J., Powderly, J., et al. PL04a.03: Durvalumab in ≥3rd-line locally advanced or metastatic, EGFR/ALK Wild-Type NSCLC: results from the Phase 2 ATLANTIC study. J Thorac Oncol 12 (2017), S10–S11, 10.1016/j.jtho.2016.11.012.
61. Gomez-Roca, C., Koscielny, S., Ribrag, V., Dromain, C., Marzouk, I., Bidault, F., et al. Tumour growth rates and RECIST criteria in early drug development. Eur J Cancer Oxf Engl 2011:47 (1990), 2512–2516, 10.1016/j.ejca.2011.06.012.
62. Lahmar J, Mezquita L, Koscielny S, Facchinetti F, Bluthgen MV, Adam J et al. Immune checkpoint inhibitors (IC) induce paradoxical progression in a subset of non-small cell lung cancer (NSCLC) | OncologyPRO, n.d. < http://oncologypro.esmo.org/Meeting-Resources/ESMO-2016/Immune-checkpoint-inhibitors-IC-induce-paradoxical-progression-in-a-subset-of-non-small-cell-lung-cancer-NSCLC> [accessed June 1, 2017].
63. Champiat, S., Dercle, L., Ammari, S., Massard, C., Hollebecque, A., Postel-Vinay, S., et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res Off J Am Assoc Cancer Res 23 (2017), 1920–1928, 10.1158/1078-0432.CCR-16-1741.
64. Hugo, W., Zaretsky, J.M., Sun, L., Song, C., Moreno, B.H., Hu-Lieskovan, S., et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165 (2016), 35–44, 10.1016/j.cell.2016.02.065.
65. Kaur, A., Webster, M.R., Marchbank, K., Behera, R., Ndoye, A., Kugel, C.H., et al. SFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature 532 (2016), 250–254, 10.1038/nature17392.
66. Bianchi-Frias D, Vakar-Lopez F, Coleman IM, Plymate SR, Reed MJ, Nelson PS. The effects of aging on the molecular and cellular composition of the prostate microenvironment. PloS One 2010;5. http://dx.doi.org/10.1371/journal.pone.0012501.
67. Bouchlaka, M.N., Murphy, W.J., Impact of aging in cancer immunotherapy: the importance of using accurate preclinical models. Oncoimmunology, 2, 2013, e27186, 10.4161/onci.2718.